Instituto Europeo di Oncologia

Site:	Instituto Europeo di Oncologia
Address:	Via Giuseppe Ripamonti, 43
City:	Milano
State:
Zip:	20141
Country:	Italy

Phase	Trial	Trial Status	Site Status	Drug [desc]	NCT#
3	A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy (StrateGIST 3)	Recruiting	Active	Velzatinib	NCT07218926
1/2	A Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies	Recruiting	Active	DCC-3116 + Ripretinib	NCT05957367
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Active, not recruiting	Active, not recruiting	Bezuclastinib plus Sunitinib	NCT05208047
2	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Recruiting	Active	Belzutifan	NCT04924075
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722